Cytokinetics

CYTK | NASDAQ

Price Alert Chart Builder DCF Calculator

$62.99

-$0.32 (-0.51%)

At close: Oct 30, 2026, 4:00 PM ET

$63.94

+$0.95 (+1.50%)

Pre-market: Nov 2, 2026, 4:52 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.51%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

43.7

+4.2 pts

Fundamentals Average

Market Sentiment Bullish

Moat Narrow

Sector Rank #434/1028 (Top 42%)

Full Analysis

Key Statistics

Market Data

Market Cap $8.76B

1D Range

62.55 64.50

52W Range

59.19 87.26

Valuation (TTM)

PE -8.72

PB -50.48

EV/EBITDA -10.83

Valuation (NTM)

Forward PE N/A

Forward PEG 1.22

Price Target $113.33

Cash Flow

FCF Yield -6.6%

SBC Adj. FCF Yield -7.7%

SBC Impact -16.7%

Margins

Gross Margin 88.8%

Operating Margin -993.0%

FCF Margin -818.4%

Growth (CAGR)

Revenue 3Y | 5Y 92.5% | 4.2%

Dil EPS 3Y | 5Y -15.7% | -14.9%

FCF 3Y | 5Y -19.1% | -16.6%

Returns

ROA -46.5%

ROE 164.0%

ROIC -39.3%

Financial Health

Net Cash

$18.6M

Current Ratio 6.66

Interest Coverage -5.64

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating ...

Sector Healthcare

Industry Biotechnology

Employees 673

IPO Date Apr 26, 2004

Website www.cytokinetics.com

Fiscal Year January - December

Full Company Profile

Latest News

4 days ago · zacks.com

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12 days ago · globenewswire.com

Cytokinetics to Announce Third Quarter Results on November 4, 2026

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.

14 days ago · globenewswire.com

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment.

14 days ago · zacks.com

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.

14 days ago · globenewswire.com

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.

21 days ago · globenewswire.com

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM

1 month ago · globenewswire.com

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.

1 month ago · globenewswire.com

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice

1 month ago · marketbeat.com

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.